GKSLGujarat Kidney And Super Speciality Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Gujarat Kidney and Super Speciality Limited operates multi-specialty and super-specialty hospitals. It provides treatment for Oncology, Neurology, Gastroenterology, Urology, Nephrology, and Physiotherapy. It also offers Renal Surgery, Vascular Surgery, Gynecology and obstetrics, Robotic Surgery, Bariatric Surgery, Laparoscopic Surgery, Endocrine Surgery, Neurosurgery, and Joint Replacement services. Its facilities include intensive care unit, patient counselling, operation theatres, and dialysis center. Gujarat Kidney And Super Speciality Limited was founded in 2014 and is headquartered in Vadodara, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on GKSL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 124.7% YoY
- • Debt/Equity: 0.11
- • Promoter holding: 74.8%
- • Price vs SMA50: above
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bull case
- • Revenue growth: 124.7% YoY
- • Debt/Equity: 0.11
- • Promoter holding: 74.8%
- • Price vs SMA50: above
Bear case
- • Profit growth: -22.4% YoY
- • ROE: 6.1%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Profit growth: -22.4% YoY
- • ROE: 6.1%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹8.65). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.